GE Medical Systems and affiliates of venture capitalist Trillium Group are the primary contributors of some $3.8 million invested in VirtualScopics as part of that company's Series C round of financing. The Pittsford, NY, provider is developing a suite
GE Medical Systems and affiliates of venture capitalist Trillium Group are the primary contributors of some $3.8 million invested in VirtualScopics as part of that company's Series C round of financing. The Pittsford, NY, provider is developing a suite of image analysis tools that detect and help characterize tiny changes in physical structures over time. The firm's image-based biomarker solutions are designed to accelerate the pharmaceutical R&D process by rapidly measuring the efficacy and safety of drug compounds. The technology might also be leveraged to improve treatment planning and diagnosis for patients. GE plans to collaborate with VirtualScopics to advance the application of its imaging technology in clinical trials. The firm's proprietary software algorithms can assemble hundreds of separate medical images taken during an MRI session into a single 3D model.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.